Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 03:06:02 2025-06-17 am EDT			5-day change	1st Jan Change
260.90 ^CHF	-0.76%		-1.98%	+2.90%

12:54am	Swiss stocks - Factors to watch on June 17	RE
Jun. 16	Sarepta shares crash as second patient dies after receiving its gene therapy	RE

ROCHE HOLDINGS AG : Sell rating from JP Morgan

Published on 04/30/2025 at 03:32

Richard Vosser from JP Morgan retains his negative opinion on the stock with a Sell rating. The target price is reduced from CHF 230 to CHF 220.

Latest news about Roche Holding AG

Swiss stocks - Factors to watch on June 17	12:54am	RE
Sarepta shares crash as second patient dies after receiving its gene therapy	Jun. 16	RE
ROCHE HOLDINGS AG : Gets a Buy rating from UBS	Jun. 16	ZD
Swiss Stocks Kick Off New Trading Week Downbeat Amid Gloomy Economic Forecasts	Jun. 16	MT
Analyst recommendations: Meta, Eli Lilly, RTX Corp, Airbus, Roche…	Jun. 16
AbbVie says blood cancer drug fails late-stage trial	Jun. 16	RE
Upcoming Fed Meeting Eyed as US Equity Futures Rise Pre-Bell	Jun. 16	MT
North American Morning Briefing : Stock Futures Rise As Israel-Iran Conflict Enters Fourth Day	Jun. 16	DJ
Prothena's Partner to Advance Potential Parkinson's Treatment to Phase 3 Development	Jun. 16	MT
Roche Pauses Commercial and Clinical Use of Elevidys After Fatal Liver Failures	Jun. 16	DJ
Roche: moving towards phase 3 in Parkinson's disease	Jun. 16	CF
Roche to Advance Prasinezumab Into Phase 3 Trial for Early-Stage Parkinson's Disease	Jun. 16	DJ
Roche to Proceed with Phase Three Development of Investigational Drug for Parkinson's Disease	Jun. 16	MT
Roche To Advance Prasinezumab Into Phase III Development For Early-Stage Parkinson's Disease	Jun. 16	RE
Swiss stocks - Factors to watch on June 16	Jun. 16	RE
Sarepta reports second case of liver failure death after its gene therapy treatment	Jun. 15	RE
Roche Updates Treatment Profile, Dosing Restrictions for Duchenne Muscular Dystrophy Treatment	Jun. 15	MT
Roche Provides Safety Update On Elevidys(TM) Gene Therapy For Duchenne Muscular Dystrophy In Non-Ambulatory Patients	Jun. 15	RE
Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial	Jun. 13	RE
US FDA approves Nuvation Bio's rare lung cancer drug	Jun. 11	RE
Roche Canada Says Health Canada Authorizes PiaSky	Jun. 11	RE
EQT, Sanofi Co-Led $135 Million Funding Round for Spanish Biotech Company SpliceBio	Jun. 11	DJ
EQT leads financing round in SpliceBio	Jun. 11	FW
Pharma Mar's Supplemental New Drug Application for Lung Cancer Drug Combo Gets US FDA Priority Review	Jun. 10	MT
Roche's Middle Eastern Arm Launches Sustainable Healthcare Lab Certification Initiative	Jun. 10	MT

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Employees

103,249

Sector

Pharmaceuticals

Calendar

2025-06-16 - International Malignant Lymphoma Conference

More about the company